Elicio Therapeutics Statistics
Share Statistics
Elicio Therapeutics has 15.95M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 15.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 27 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.2 and the forward
PE ratio is -2.02.
Elicio Therapeutics's PEG ratio is
0.03.
| PE Ratio | -1.2 |
| Forward PE | -2.02 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -5.5 |
| P/FCF Ratio | -1.68 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Elicio Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.8,
with a Debt / Equity ratio of -2.3.
| Current Ratio | 1.8 |
| Quick Ratio | 1.8 |
| Debt / Equity | -2.3 |
| Debt / EBITDA | -0.58 |
| Debt / FCF | -0.7 |
| Interest Coverage | 98.87 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,621,812.5 |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -40.09% in the
last 52 weeks. The beta is 0.93, so Elicio Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.93 |
| 52-Week Price Change | -40.09% |
| 50-Day Moving Average | 6.61 |
| 200-Day Moving Average | 5.68 |
| Relative Strength Index (RSI) | 47.07 |
| Average Volume (20 Days) | 41,065 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -44.99M |
| Net Income | -51.9M |
| EBITDA | -44.99M |
| EBIT | -52.35M |
| Earnings Per Share (EPS) | -4.25 |
Full Income StatementBalance Sheet
The company has 17.62M in cash and 26.04M in
debt, giving a net cash position of -8.42M.
| Cash & Cash Equivalents | 17.62M |
| Total Debt | 26.04M |
| Net Cash | -8.42M |
| Retained Earnings | -194.1M |
| Total Assets | 28.18M |
| Working Capital | 9.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -37.07M
and capital expenditures -87K, giving a free cash flow of -37.16M.
| Operating Cash Flow | -37.07M |
| Capital Expenditures | -87K |
| Free Cash Flow | -37.16M |
| FCF Per Share | -3.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
